Compare Abbott Laboratories (ABT) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Rivian Automotive, Inc. — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Rivian Automotive, Inc. trades at $16.46 (market cap $22.44B). The key difference: Abbott Laboratories is far larger — about 7.4× Rivian Automotive, Inc.'s market cap, and Abbott Laboratories pays a 2.63% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals.
| ABT | RIVN | |
|---|---|---|
Market Cap | $166.94B | $22.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $22.45 |
52-Week Low | $82.57 | $11.64 |
Enterprise Value | $193.69B | $24.19B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Rivian (RIVN) trades at $16.49, down 11.49% amid a 75 million share offering announced July 7, 2026, raising dilution concerns despite recent quarterly EPS beats. The stock shows a bullish technical signal with moving averages supporting upside, but RSI indicates overbought conditions. Revenue grew to $5.39B in 2025, yet net losses persist at -$3.65B, with cash flow negative but improving. Analyst consensus is mixed with a $21.29 price target.
Outlook remains challenged by high cash burn and dilution risks, but cost reductions and DOE loan potential offer long-term growth avenues. Investors face volatility from EV competition and execution hurdles, though institutional buy ratings suggest cautious optimism for profitability milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
